My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer - Episode 7

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

May 1, 2023

Andrew J. Armstrong, MD, Matthew Manning, MD

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 2: Approved Treatment Options for Patients with mCRPC

EP. 3: Patient Profile: A 78-Year-Old Man with mCRPC

EP. 4: Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

EP. 5: Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

EP. 6: Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

Now Viewing

EP. 7: Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

EP. 8: Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

EP. 9: Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

EP. 10: Closing Thoughts on the Future of mCRPC Treatment